Effect of ischaemic preconditioning on regional release of inflammatory markers

Tsung-Ming Lee1, Mei-Shu Lin, Chang-Her Tsai

  • 1Cardiology Section, Department of Medicine, Chi-Mei Medical Centre, Taipei Medical University, Tainan, Taiwan.

Insights

Ischaemic preconditioning (IP) reduces inflammation after coronary angioplasty by activating ATP-sensitive potassium (KATP) channels. This anti-inflammatory effect prevents the release of key markers like P-selectin and myeloperoxidase.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Interventional Cardiology

Background:

  • Systemic inflammation markers can increase post-percutaneous coronary intervention (PCI).
  • Ischaemic preconditioning (IP) is known for cardioprotection, but its anti-inflammatory role needs clarification.
  • ATP-sensitive potassium (KATP) channels are implicated in various cellular processes, including inflammation.

Purpose of the Study:

  • To investigate if IP attenuates inflammation following coronary angioplasty.
  • To determine the role of KATP channels in mediating the anti-inflammatory effects of IP.
  • To assess the impact of IP and KATP channel modulation on specific inflammatory markers.

Main Methods:

  • A randomized study involving 36 patients undergoing coronary angioplasty.
  • Four groups: control, nicorandil (KATP channel agonist), IP, and IP with glibenclamide (KATP channel antagonist).
  • Measurement of sCD40L, P-selectin, and myeloperoxidase in the aorta and great cardiac vein before and after angioplasty.

Main Results:

  • Coronary angioplasty increased sCD40L and P-selectin in the great cardiac vein in the control group.
  • IP and nicorandil treatments prevented significant increases in sCD40L and P-selectin.
  • Glibenclamide abolished the anti-inflammatory effect of IP, and myeloperoxidase levels mirrored these changes.
  • No significant changes in aortic inflammatory markers were observed.

Conclusions:

  • IP effectively abolishes angioplasty-induced myeloperoxidase release.
  • IP prevents P-selectin release, mediated by activated platelets, through a KATP-channel pathway.
  • IP offers potential anti-inflammatory benefits beyond cardioprotection by modulating platelet-neutrophil interactions.

Related Concept Videos